Department of Radiation Oncology, Faculty of Medicine.
Leuk Lymphoma. 2013 Nov;54(11):2474-9. doi: 10.3109/10428194.2013.779691. Epub 2013 Mar 27.
Conditioning regimens used during stem cell transplant provide prolonged control or cure of the disease in patients with acute lymphoblastic leukemia (ALL). In this study, we present a comparison of treatment results for 95 patients with ALL who underwent allogeneic hematopoietic stem cell transplant (AHSCT) with total body irradiation plus cyclophosphamide (TBI + Cy) or busulfan plus cyclophosphamide (Bu + Cy) as conditioning regimen. Median age was 25 (range: 9-54) years. Median follow-up was 24 (range: 3-107) months. Median overall survival (OS) was found to be 29 months. Median event-free survival (EFS) was 9 months. Median OS was 37 months in the TBI + Cy arm, while it was 12 months in the Bu + Cy arm, suggesting a significant advantage favoring the TBI + Cy arm (p = 0.003). Median EFS was 13 months in the TBI + Cy arm, while it was 4 months in the Bu + Cy arm, indicating a significant difference (p = 0.006). In univariate and multivariate analysis, it was found that high OS and EFS were significantly correlated with TBI + Cy conditioning regimen and lack of transplant-related mortality (p < 0.05). The TBI + Cy conditioning regimen was found to be superior to the Bu + Cy regimen in patients with ALL undergoing AHSCT regarding both OS and EFS.
在干细胞移植中使用的预处理方案可在急性淋巴细胞白血病(ALL)患者中提供疾病的长期控制或治愈。在这项研究中,我们比较了 95 例接受异基因造血干细胞移植(AHSCT)的 ALL 患者的治疗结果,这些患者使用全身照射加环磷酰胺(TBI + Cy)或白消安加环磷酰胺(Bu + Cy)作为预处理方案。中位年龄为 25 岁(范围:9-54 岁)。中位随访时间为 24 个月(范围:3-107 个月)。中位总生存期(OS)为 29 个月。中位无事件生存期(EFS)为 9 个月。TBI + Cy 组的中位 OS 为 37 个月,而 Bu + Cy 组的中位 OS 为 12 个月,表明 TBI + Cy 组具有显著优势(p = 0.003)。TBI + Cy 组的中位 EFS 为 13 个月,而 Bu + Cy 组的中位 EFS 为 4 个月,差异有统计学意义(p = 0.006)。在单变量和多变量分析中,发现高 OS 和 EFS 与 TBI + Cy 预处理方案和无移植相关死亡率显著相关(p < 0.05)。在 ALL 患者接受 AHSCT 时,与 Bu + Cy 方案相比,TBI + Cy 方案在 OS 和 EFS 方面均具有优势。